Allergy Therapeutics PLC (GB:AGY)
LSE:AGY
Want to see GB:AGY full AI Analyst Report?
AGY Stock Chart & Stats
11.80 p
-0.04 p(-0.55%)
At close: 4:00 PM EST
11.80 p
-0.04 p(-0.55%)
Day’s Range― - ―
52-Week Range5.50 p - 12.10 p
Previous CloseN/A
Volume22.64K
Average Volume (3M)460.33K
Market Cap
£690.25M
Enterprise Value546.08M
Total Cash (Recent Filing)£10.08M
Total Debt (Recent Filing)£26.75M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Sep 30, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding6,332,530,000
10 Day Avg. Volume433,490
30 Day Avg. Volume460,334
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£68.00M
Bulls Say, Bears Say
Bulls Say
Focused Niche Product PortfolioA clear, focused business model on allergy immunotherapy creates durable competitive advantages: deep domain expertise, targeted R&D, and tailored commercial pathways. Specialization supports higher barriers to entry, reproducible clinical know-how, and long-term customer relationships with clinics and allergists.
Diversified Commercial Channels And PartnershipsMultiple revenue channels (direct sales, distributor partnerships, licensing, co-development) reduce single-channel dependence and support scale-up. Structural partnerships expand market reach, lower distribution risk, and enable non-dilutive funding paths for pipeline advancement over the next several quarters.
Operational Scale And Improving Per-share MetricsA workforce of 612 indicates substantive R&D, clinical and commercial capacity to advance products and manage launches. Reported EPS growth suggests improving per-share performance or earnings dynamics, which, alongside headcount, supports sustained pipeline execution and longer-term commercial rollouts.
Bears Say
Declining Revenue TrendSustained revenue decline erodes the commercial base needed to fund R&D and scale manufacturing. A shrinking top line reduces operating leverage, limits reinvestment capacity, and makes it harder to absorb fixed costs, increasing reliance on external financing to sustain operations over months.
Large Losses And Weak MarginsDeep negative margins and persistent operating cash burn constrain internal funding for product development and commercialization. Negative EBIT/EBITDA and free cash flow signal the company must raise capital or cut investment, which can delay clinical programs and weaken long-term competitiveness.
Stressed Balance Sheet And LeverageNegative equity and high leverage materially increase refinancing and solvency risk. A stressed balance sheet reduces strategic flexibility, raises borrowing costs, and can limit ability to fund commercial expansion or enter partnerships, posing a structural constraint on executing long-term plans.
Allergy Therapeutics News
AGY FAQ
What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest share price was 5.50 p and its highest was 12.10 p in the past 12 months.
What is Allergy Therapeutics PLC’s market cap?
Allergy Therapeutics PLC’s market cap is £690.25M.
When is Allergy Therapeutics PLC’s upcoming earnings report date?
Allergy Therapeutics PLC’s upcoming earnings report date is Sep 30, 2026 which is in 163 days.
How were Allergy Therapeutics PLC’s earnings last quarter?
Allergy Therapeutics PLC released its earnings results on Mar 31, 2026. The company reported -0.004 p earnings per share for the quarter, the consensus estimate of -0.004 p by 0 p.
Is Allergy Therapeutics PLC overvalued?
According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued.
Does Allergy Therapeutics PLC pay dividends?
Allergy Therapeutics PLC does not currently pay dividends.
What is Allergy Therapeutics PLC’s EPS estimate?
Allergy Therapeutics PLC’s EPS estimate is >-0.01.
How many shares outstanding does Allergy Therapeutics PLC have?
Allergy Therapeutics PLC has 6,332,530,000 shares outstanding.
What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
Allergy Therapeutics PLC reported an EPS of -0.004 p in its last earnings report, expectations of -0.004 p. Following the earnings report the stock price went down -1.905%.
Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AGY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allergy Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.35%
12-Months-Change
Fundamentals
Return on Equity
409.00%
Trailing 12-Months
Asset Growth
-2.69%
Trailing 12-Months
Company Description
Allergy Therapeutics PLC
Allergy Therapeutics (AGY) is a biotechnology company focused on the development and commercialization of innovative allergy immunotherapy products. The company specializes in providing treatments for allergic conditions, primarily targeting pollen, dust mites, and animal allergens. Its core product offerings include allergy vaccines and immunotherapy solutions designed to alleviate symptoms and improve the quality of life for patients suffering from allergies. AGY operates primarily within the healthcare sector, leveraging cutting-edge research to develop effective therapies for allergy sufferers worldwide.
Technical Analysis
Animalcare
―
Hikma Pharmaceuticals
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---